MUMBAI, 24 September 2026 — Green Asia Impex Limited’s SME offer is scheduled to begin today at ₹85–₹90 per share. Its NSE issue-detail record gives a ₹53.10 crore fresh component and ₹7 crore offer for sale, adding to ₹60.10 crore.
Verified details
| Company | Green Asia Impex Limited |
|---|---|
| Application window | 24-Sep-2026 to 28-Sep-2026 |
| Price band | Rs.85 to Rs.90 per equity share |
| Quoted lot unit | 1600 Equity Shares and in multiples thereof |
| Registrar | Bigshare Services Private Limited |
Why the headline amount needs a split
Around 88.35% of that stated monetary offer is fresh issuance and 11.65% is a sale by existing holders. Only the fresh component can provide gross capital to the business. Costs and the approved use-of-proceeds schedule still need to be considered before treating that gross figure as cash available for expansion.
A lot unit is not automatically the minimum application
The quoted trading lot is 1,600 shares, worth ₹136,000 at ₹85 or ₹144,000 at ₹90. Those figures value one lot only. This report does not label one lot the minimum permitted SME application: category-specific minimums and current offer rules must be checked in the application documents and broker interface.
Different cut-offs need attention
Bidding is scheduled to finish September 28. NSE’s detail page specifies 4 p.m. bidding closure on the last day, while its UPI mandate deadline is 5 p.m. The later mandate time does not extend the bidding session. Bigshare Services is registrar and Indorient Financial Services is lead manager. No reliable pre-opening demand multiple is available. The source record also contains a 355,200-share market-maker allocation, already included rather than additional to the offer.
Source check: CapKet retrieved the linked exchange records at approximately 00:57 IST on 24 September 2026. Event dates and source update times are distinguished from this publication date. Later corrections may change the official record.
Disclosure: AI-assisted, independently written reporting from attributed public records; no independent human review is claimed. This is general information, not an investment recommendation. No listing return, dividend receipt or buyback acceptance is guaranteed.